JP2014528695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528695A5 JP2014528695A5 JP2014517198A JP2014517198A JP2014528695A5 JP 2014528695 A5 JP2014528695 A5 JP 2014528695A5 JP 2014517198 A JP2014517198 A JP 2014517198A JP 2014517198 A JP2014517198 A JP 2014517198A JP 2014528695 A5 JP2014528695 A5 JP 2014528695A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- fragment
- synuclein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 122
- 239000000427 antigen Substances 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 102000040430 polynucleotide Human genes 0.000 claims description 57
- 108091033319 polynucleotide Proteins 0.000 claims description 57
- 239000002157 polynucleotide Substances 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 18
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 16
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 16
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 16
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 16
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000004807 localization Effects 0.000 claims description 9
- 102000019355 Synuclein Human genes 0.000 claims description 8
- 108050006783 Synuclein Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 238000011503 in vivo imaging Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000008512 biological response Effects 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 101000787265 Homo sapiens Beta-synuclein Proteins 0.000 claims description 2
- 101000787273 Homo sapiens Gamma-synuclein Proteins 0.000 claims description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 101000834887 Mus musculus Alpha-synuclein Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims description 2
- 238000012634 optical imaging Methods 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- -1 pharmaceutical Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500580P | 2011-06-23 | 2011-06-23 | |
| US61/500,580 | 2011-06-23 | ||
| PCT/US2012/043701 WO2012177972A1 (en) | 2011-06-23 | 2012-06-22 | Anti-alpha synuclein binding molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016159621A Division JP6302517B2 (ja) | 2011-06-23 | 2016-08-16 | 抗アルファシヌクレイン結合分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014528695A JP2014528695A (ja) | 2014-10-30 |
| JP2014528695A5 true JP2014528695A5 (enExample) | 2015-07-16 |
Family
ID=47422964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517198A Withdrawn JP2014528695A (ja) | 2011-06-23 | 2012-06-22 | 抗アルファシヌクレイン結合分子 |
| JP2016159621A Expired - Fee Related JP6302517B2 (ja) | 2011-06-23 | 2016-08-16 | 抗アルファシヌクレイン結合分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016159621A Expired - Fee Related JP6302517B2 (ja) | 2011-06-23 | 2016-08-16 | 抗アルファシヌクレイン結合分子 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9580493B2 (enExample) |
| EP (1) | EP2723379B1 (enExample) |
| JP (2) | JP2014528695A (enExample) |
| KR (1) | KR101976887B1 (enExample) |
| CN (1) | CN103796679B (enExample) |
| AU (1) | AU2012272790B2 (enExample) |
| BR (1) | BR112013033258B1 (enExample) |
| CA (1) | CA2839563C (enExample) |
| CY (1) | CY1121392T1 (enExample) |
| DK (1) | DK2723379T3 (enExample) |
| EA (1) | EA030777B9 (enExample) |
| ES (1) | ES2699801T3 (enExample) |
| HR (1) | HRP20181553T1 (enExample) |
| HU (1) | HUE041391T2 (enExample) |
| IL (1) | IL230028B (enExample) |
| LT (1) | LT2723379T (enExample) |
| MX (1) | MX357193B (enExample) |
| PL (1) | PL2723379T3 (enExample) |
| PT (1) | PT2723379T (enExample) |
| SI (1) | SI2723379T1 (enExample) |
| TR (1) | TR201815563T4 (enExample) |
| WO (1) | WO2012177972A1 (enExample) |
| ZA (1) | ZA201309623B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US9994609B2 (en) | 2013-03-15 | 2018-06-12 | Biogen Ma Inc. | Hydrophobic interaction protein chromatography under no-salt conditions |
| EP3184634B1 (en) | 2014-08-22 | 2019-10-16 | Nitto Boseki Co., Ltd. | PROTEIN ASSAY METHOD SPECIFIC TO TRACP-5b (TARTRATE RESISTANT ACID PHOSPHATASE 5b) |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| PL3430397T3 (pl) | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
| TW202309093A (zh) | 2016-06-02 | 2023-03-01 | 英商梅迪繆思有限公司 | 針對α-突觸核蛋白之抗體及其用途 |
| MA45715A (fr) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | Anticorps anti-hspa5 (grp78) et leurs utilisations |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| JP2018109560A (ja) | 2017-01-04 | 2018-07-12 | オムロンオートモーティブエレクトロニクス株式会社 | 走査式距離測定装置 |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| JOP20190227A1 (ar) * | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| EP3661961A4 (en) * | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| EP3672635A4 (en) | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF |
| US20190153102A1 (en) | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| CA3076313A1 (en) * | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| BR112020009707A2 (pt) * | 2017-11-17 | 2020-10-13 | Abl Bio Inc. | anticorpos para a-sinucleína e usos dos mesmos |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| EP3833435B1 (en) | 2018-08-09 | 2025-09-24 | F. Hoffmann-La Roche AG | Determination of parkinson's disease |
| MA54070A (fr) | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| US20230075314A1 (en) * | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| EP3998286A4 (en) * | 2019-07-11 | 2023-04-26 | Wuhan Yzy Biopharma Co., Ltd. | QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES |
| US12318357B2 (en) | 2019-08-02 | 2025-06-03 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| MX2022013173A (es) | 2020-04-24 | 2022-11-30 | Hoffmann La Roche | Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados. |
| HRP20250812T1 (hr) * | 2020-06-26 | 2025-09-12 | Bioarctic Ab | Antitijela koja vežu alfa-sinuklein protofibril |
| JP7898188B2 (ja) * | 2020-08-04 | 2026-07-31 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
| TW202227131A (zh) | 2020-09-10 | 2022-07-16 | 愛爾蘭商普羅佘納生物科技有限公司 | 帕金森氏症之治療 |
| CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN117106081B (zh) * | 2023-09-28 | 2024-05-07 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
| CN119751671B (zh) * | 2025-01-17 | 2025-07-11 | 首都医科大学宣武医院 | 一种特异性结合α-突触核蛋白的抗体及其相关产品和用途 |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2149326C (en) | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Fully impaired consensus kozak sequences for mammalian expression |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| AU721898B2 (en) | 1994-11-18 | 2000-07-20 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| SI0994728T1 (sl) | 1997-04-09 | 2009-02-28 | Intellect Neurosciences Inc | Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| AU3117799A (en) | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| CA2274414A1 (en) | 1999-06-11 | 2000-12-11 | Universite Laval | Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals |
| JP2003509020A (ja) | 1999-09-03 | 2003-03-11 | ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド | プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法 |
| US6187309B1 (en) | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
| US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
| US6713058B2 (en) | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
| US6436401B1 (en) | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
| IL153375A0 (en) * | 2000-06-22 | 2003-07-06 | Genentech Inc | Agonist anti-trk-c monoclonal antibodies |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| ITPV20010007U1 (it) | 2001-07-19 | 2003-01-19 | Maruscia Food Specialties Comp | Contenitore per profilattico nuovo e usato |
| EP1944040B1 (en) | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
| US7414111B2 (en) * | 2001-09-19 | 2008-08-19 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| AU2003284427A1 (en) | 2002-11-22 | 2004-06-18 | Chugai Seiyaku Kabushiki Kaisha | Antibody against lesion tissue |
| WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP4851348B2 (ja) | 2004-02-23 | 2012-01-11 | イーライ リリー アンド カンパニー | 抗Ａβ抗体 |
| CA2564432A1 (en) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
| WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| WO2006050041A2 (en) | 2004-10-28 | 2006-05-11 | Ramot At Tel Aviv University Ltd. | Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| US20060257396A1 (en) | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
| KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| JP2006265189A (ja) | 2005-03-24 | 2006-10-05 | Kyoto Univ | βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法 |
| ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| WO2006116192A2 (en) | 2005-04-21 | 2006-11-02 | Medarex, Inc. | Irta-1 antibodies and their uses |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2009521403A (ja) | 2005-11-14 | 2009-06-04 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Ｍｒｉによる神経発生の相関の画像法 |
| WO2007062088A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
| JP2009518010A (ja) | 2005-11-30 | 2009-05-07 | アボット・ラボラトリーズ | ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用 |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| NZ568012A (en) | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| HUE033325T2 (en) | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| PL2457928T3 (pl) | 2007-03-13 | 2017-10-31 | Univ Zuerich | Monoklonalne ludzkie przeciwciało swoiste względem nowotworu |
| WO2008131298A2 (en) | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| WO2008148884A1 (en) * | 2007-06-08 | 2008-12-11 | Universite De La Mediterranee | Compositions and methods for treating pancreatic tumors |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JP2010536907A (ja) | 2007-08-31 | 2010-12-02 | ニューリミューン セラピューティクス エイジー | 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法 |
| EP2527369A3 (en) | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| KR101652125B1 (ko) * | 2007-09-26 | 2016-08-29 | 우드라이 파마 게엠베하 | 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질 |
| KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| GB0720912D0 (en) | 2007-10-25 | 2007-12-05 | Univ Cardiff | Monoclonal Anitbody for APP |
| CN101883792B (zh) | 2007-10-29 | 2014-08-27 | 基因创新有限公司 | 特异于β-淀粉状蛋白肽的新抗体以及其用作诊断剂或药物的用途 |
| AU2008322523B2 (en) | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| WO2009085200A2 (en) * | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| WO2010004434A2 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| CA2737667A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Targeted binding agents directed to cd105 and uses thereof |
| CN102271669A (zh) | 2008-11-13 | 2011-12-07 | 基因改造有限责任公司 | 非大脑组织中β-淀粉样肽负载的改性 |
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| JP5015984B2 (ja) * | 2009-03-18 | 2012-09-05 | 株式会社コナミデジタルエンタテインメント | ゲームサーバ、ゲームシステム、ゲーム装置、巡回地点更新方法、および、プログラム |
| US20100256596A1 (en) | 2009-04-07 | 2010-10-07 | Cabochon Aesthetics, Inc. | Fiber growth promoting implants for reducing the appearance of cellulite |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| CN102596997B (zh) | 2009-08-06 | 2015-06-03 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| US8378061B2 (en) | 2009-09-02 | 2013-02-19 | E.I. Du Pont De Nemours And Company | Polyester films with improved oil repellency |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| MX356797B (es) | 2011-11-02 | 2018-06-14 | Biogen Int Neuroscience Gmbh | Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro. |
| ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
-
2012
- 2012-06-22 PL PL12802721T patent/PL2723379T3/pl unknown
- 2012-06-22 ES ES12802721T patent/ES2699801T3/es active Active
- 2012-06-22 EA EA201391761A patent/EA030777B9/ru unknown
- 2012-06-22 AU AU2012272790A patent/AU2012272790B2/en not_active Ceased
- 2012-06-22 EP EP12802721.6A patent/EP2723379B1/en active Active
- 2012-06-22 SI SI200831997T patent/SI2723379T1/sl unknown
- 2012-06-22 BR BR112013033258-1A patent/BR112013033258B1/pt not_active IP Right Cessation
- 2012-06-22 HU HUE12802721A patent/HUE041391T2/hu unknown
- 2012-06-22 JP JP2014517198A patent/JP2014528695A/ja not_active Withdrawn
- 2012-06-22 US US14/128,497 patent/US9580493B2/en not_active Expired - Fee Related
- 2012-06-22 CA CA2839563A patent/CA2839563C/en active Active
- 2012-06-22 TR TR2018/15563T patent/TR201815563T4/tr unknown
- 2012-06-22 LT LTEP12802721.6T patent/LT2723379T/lt unknown
- 2012-06-22 KR KR1020147001723A patent/KR101976887B1/ko not_active Expired - Fee Related
- 2012-06-22 HR HRP20181553TT patent/HRP20181553T1/hr unknown
- 2012-06-22 MX MX2014000054A patent/MX357193B/es active IP Right Grant
- 2012-06-22 PT PT12802721T patent/PT2723379T/pt unknown
- 2012-06-22 DK DK12802721.6T patent/DK2723379T3/en active
- 2012-06-22 CN CN201280039104.2A patent/CN103796679B/zh not_active Expired - Fee Related
- 2012-06-22 WO PCT/US2012/043701 patent/WO2012177972A1/en not_active Ceased
-
2013
- 2013-12-19 IL IL230028A patent/IL230028B/en active IP Right Grant
- 2013-12-19 ZA ZA2013/09623A patent/ZA201309623B/en unknown
-
2016
- 2016-08-16 JP JP2016159621A patent/JP6302517B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-19 US US15/410,128 patent/US9975947B2/en not_active Expired - Fee Related
-
2018
- 2018-03-07 US US15/914,110 patent/US10301381B2/en active Active
- 2018-12-10 CY CY20181101312T patent/CY1121392T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101600733B1 (ko) | 알파-시누클레인을 인식하는 인간화된 항체 | |
| CN105121473B (zh) | α-突触核蛋白抗体及其用途 | |
| CN104619724B (zh) | 识别α-突触核蛋白的人源化抗体 | |
| JP2012518425A5 (enExample) | ||
| CA2791538C (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| JP7852904B2 (ja) | 免疫調節抗体およびその使用方法 | |
| JP2020124203A (ja) | 血液脳関門輸送分子およびそれらの使用 | |
| CA3111569A1 (en) | Anti-trem-2 agonist antibodies | |
| JP2012512634A5 (enExample) | ||
| EP2563816B1 (en) | Anti-icam-1 single domain antibody and uses thereof | |
| CN102686609A (zh) | 修饰的可变域分子及其生产和使用方法 | |
| CN108368160A (zh) | 淀粉样蛋白β中的C-末端表位及其构象选择性抗体 | |
| JP2017522886A5 (enExample) | ||
| JP7539536B2 (ja) | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 | |
| US20210379194A1 (en) | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications | |
| JP7210612B2 (ja) | 抗ａベータ抗体及びその使用 | |
| US20250042976A1 (en) | Monoclonal antibodies specific for sars-cov-2 rbd | |
| JP2022538688A5 (enExample) | ||
| WO2025167135A1 (zh) | 抗s100a8/a9抗体及其用途 | |
| CN117510636B (zh) | Gprc5d抗体及其应用 | |
| KR20250116724A (ko) | 항-헌팅틴 항체 | |
| JP7564882B2 (ja) | Ａｒｅｇに対する抗体及びその用途 | |
| EP4543916A1 (en) | Anti-transthyretin (ttr) binding proteins and uses thereof | |
| CN111918875A (zh) | 构象-特异性的抗神经毒性tau蛋白的抗体 | |
| JP2015007030A (ja) | ＩｇＳＦ４／ＴＳＬＣ１／ＣＡＤＭ１を特異的に認識できる抗体 |